Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06812078 · ClinicalTrials.gov registry record · Phase 2

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

A Phase 2 study of Idiopathic Hypersomnia, sponsored by Takeda.

Recruiting
Registry status
Phase 2
Development phase
96
Enrollment target
20
Study locations

NCT06812078 is a Phase 2 study of Idiopathic Hypersomnia that is actively recruiting participants, run by Takeda. The registered enrollment target is 96 participants, below the 108-participant average among 7 other Idiopathic Hypersomnia trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06812078, a Phase 2 study of Idiopathic Hypersomnia, is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
20
Study locations

Study Summary

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Conditions Studied

Idiopathic Hypersomnia

Interventions

  • OTHER Placebo
  • DRUG TAK-360

Study Locations (20)

California

  • Takeda Site 11 - Redwood City
  • Takeda Site 10 - Santa Ana

Florida

  • Takeda Site 19 - Brandon
  • Takeda Site 14 - Winter Park

North Carolina

  • Takeda Site 16 - Denver
  • Takeda Site 15 - Huntersville

Ohio

  • Takeda Site 12 - Cincinnati
  • Takeda Site 17 - Cincinnati

Other

  • Takeda Site 2 - Paris
  • Takeda Site 4 - Shatin

Colorado

  • Takeda Site 27 - Colorado Springs

Missouri

  • Takeda Site 29 - St Louis

South Carolina

  • Takeda Site 13 - Columbia

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2025-02-07
Est. Completion 2026-07-16
Phase Phase 2

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06812078

The ClinicalTrials.gov registry entry for NCT06812078 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 7 other Idiopathic Hypersomnia trials with a reported enrollment target (11% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Hypersomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06812078 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06812078 about?

NCT06812078 is a clinical study titled "A Study of TAK-360 in Adults With Idiopathic Hypersomnia". Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feelin...

What is the current status of trial NCT06812078?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-02-07. Estimated completion is 2026-07-16.

What conditions does trial NCT06812078 study?

This clinical trial studies the following conditions: Idiopathic Hypersomnia.

What interventions are being tested in trial NCT06812078?

The interventions under investigation include: Placebo (OTHER), TAK-360 (DRUG).

Who is sponsoring clinical trial NCT06812078?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06812078 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Hypersomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Hypersomnia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.